Plexxikon announced positive data from its Phase 3 study of PLX4032 (RG7204) in patients with previously untreated metastatic melanoma with the BRAF mutation. This trial (known as the BRIM3 trial) is ...
Immunohistochemical expression of Dicer in melanoma. Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with PLX4032 (RG7204), in a ...
Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients
Plexxikon Inc. today announced preliminary data from a Phase 1 clinical study investigating PLX4032 (R7204). PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E ...
Clever cancers Australian and US researchers have discovered that melanomas have developed several ways to outsmart a promising experimental cancer pill called PLX4032. But the researchers say the ...
BERKELEY, Calif. & CHICAGO--(BUSINESS WIRE)--Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single ...
Group was evaluating data from a clinical study of Plexxikon’s PLX4032. Melanoma patients whose cancers are caused by BRAF gene mutation become resistant to Plexxikon’s expertimental drug through ...
BERKELEY, Calif.--(BUSINESS WIRE)-- Plexxikon Inc. today announced positive data from an interim analysis of the BRIM3 trial, a large multi-center Phase 3 clinical study of PLX4032 (RG7204) in ...
Plexxikon Inc. and Roche have announced they have entered into an agreement to develop and commercialize PLX4032, Plexxikon’s investigational targeted cancer therapy which selectively inhibits ...
Plexxikon Inc.'s and Roche AG's melanoma drug PLX4032 (RG7204) continued its streak of stellar data, with results from an open-label Phase II trial showing a 52 percent response rate in patients with ...
A large proportion of melanomas harbour the activating BRAF V600E mutation that renders these cells dependent on MAPK signalling for their survival. Although the highly specific and clinically ...
PLX4032 is related to the previously reported compound PLX4720 and was developed using a crystallography-guided approach. This allowed the optimization of the compound for preferential binding to ...
BERKELEY, Calif.--(BUSINESS WIRE)--Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company. The purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results